Ondine Announces Proposed Share Consolidation and Name Change

 
TIDMOBP 
 
Ondine Announces Proposed Share Consolidation and Name Change 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
September 29, 2010 
 
Ondine Announces Proposed Share Consolidation and Name Change 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 29, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) ("Ondine" 
or the "Company") today announced its intention to consolidate its issued and outstanding common shares and to change 
its name to Ondine Biomedical Inc., to more accurately reflect the nature of its operations. The Company does not 
anticipate changing its trading symbol. 
 
Under the proposed consolidation, every fifteen (15) existing shares will be consolidated into one (1) new share (the 
"Consolidation"). The Company currently has 126,796,145 common shares issued and outstanding. Upon completion following 
receipt of regulatory approvals, Ondine would have approximately 8,453,042 common shares issued and outstanding, after 
adjusting for fractional shares. Fractional shares remaining after giving effect to the Consolidation will be cancelled, 
such that shareholdings of each shareholder will be rounded down to the nearest whole number of post-consolidation 
common shares. Outstanding stock options and warrants will similarly be adjusted by the Consolidation ratio. 
 
In accordance with the articles of the Company, which were approved by the shareholders, the Board of Directors has the 
authority to effect the name change and the share consolidation by directors' resolution and the Company does not intend 
to seek shareholder approval for these changes. The Consolidation and name change are subject to the approval of the 
Toronto Stock Exchange. If the Consolidation proceeds, the Company will issue a subsequent news release indicating the 
record date of the Consolidation and the date on which the Company's shares will commence trading on a post 
consolidation basis. 
 
Management believes that consolidating the Company's issued common share capital would be in the best interests of the 
Company. In the opinion of Management, the share consolidation will improve the ability of the Company to attract 
additional equity financing necessary to continue with its existing business, the development and commercialization of 
photodisinfection products for the medical market. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral 
infections. The Company is focused on developing leading edge products utilizing its patented light-activated 
technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and 
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and 
development laboratory in Bothell, Washington, USA. 
 
For additional information, please visit the Company's website at: www.ondinebiopharma.com. 
 
Cautionary Statements: 
 
Completion of the proposed Consolidation is subject to a number of conditions, including but not limited to, the Toronto 
Stock Exchange acceptance. There can be no assurance that the Consolidation will be completed as proposed, or on a 
specific date, or at all. There can be no assurance that the market price of the post-consolidated common shares of the 
Company will increase as a result of the proposed Consolidation. The marketability and trading liquidity of the post- 
consolidated common shares of the Company may not improve as a result of the Consolidation. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other 
similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could 
cause actual results to differ materially from those projected in the Company's forward-looking statements include the 
following: market acceptance of our technologies and products; our ability to obtain financing; our financial and 
technical resources relative to those of our competitors; our ability to keep up with rapid technological change; 
government regulation of our technologies; our ability to enforce our intellectual property rights and protect our 
proprietary technologies; our ability to obtain regulatory approvals, our ability to obtain and develop partnership 
opportunities; the timing of commercial product launches; our ability to achieve key technical milestones in key 
products and other risk factors identified from time to time in the Company's public filings. 
 
 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
[phone] 
[e-mail] 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Genuity Limited 
Ryan Gaffney 
Nominated Adviser 
[phone] 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. 
 
 
 
 
Ondine Biopharma Corporation